Advanced NSCLC patients harboring mutated ARID1 may develop a phenotype in the tumor microenvironment (TME) that is sensitive to ICI therapy, which is characterized by the enhancement of PD-L1 expression and elevation in the TMB score. The gene discussed is CD274; the disease is non-small cell lung carcinoma.